On October 27th, on the heels of the release of the Government Accountability Office’s report in which the Office is critical of FDA’s oversight of clinical investigators (see our previous post), Rep. Joe Barton (R-TX) introduced H.R.3932, the Strengthening of FDA Integrity Act of 2009. The bill, if enacted, would amend the FDC Act to give FDA greater authority to debar individuals, including clinical investigators, from working with drug or device approvals. The bill has seven Republican co-sponsors. A summary of the bill provided by Rep. Barton is available here.